Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma

Oncogene volume 29, pages 4905–4913 (2010)Cite this article

Subjects

Abstract

Resistance to chemotherapy in ovarian cancer is poorly understood. Evolutionary models of cancer predict that, following treatment, resistance emerges either because of outgrowth of an intrinsically resistant sub-clone or evolves in residual disease under the selective pressure of treatment. To investigate genetic evolution in high-grade serous (HGS) ovarian cancers, we first analysed cell line series derived from three cases of HGS carcinoma before and after platinum resistance had developed (PEO1, PEO4 and PEO6; PEA1 and PEA2; and PEO14 and PEO23). Analysis with 24-colour fluorescence in situ hybridisation and single nucleotide polymorphism (SNP) array comparative genomic hybridisation (CGH) showed mutually exclusive endoreduplication and loss of heterozygosity events in clones present at different time points in the same individual. This implies that platinum-sensitive and -resistant disease was not linearly related, but shared a common ancestor at an early stage of tumour development. Array CGH analysis of six paired pre- and post-neoadjuvant treatment HGS samples from the CTCR-OV01 clinical study did not show extensive copy number differences, suggesting that one clone was strongly dominant at presentation. These data show that cisplatin resistance in HGS carcinoma develops from pre-existing minor clones but that enrichment for these clones is not apparent during short-term chemotherapy treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  • Agarwal R, Kaye SB . (2003). Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3: 502–516.

    Article  CAS  Google Scholar 

  • Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R et al. (2010). Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 221: 49–56.

    Article  CAS  Google Scholar 

  • Ahmed AA, Mills AD, Ibrahim AE, Temple J, Blenkiron C, Vias M et al. (2007). The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell 12: 514–527.

    Article  CAS  Google Scholar 

  • Alsop AE, Teschendorff AE, Edwards PA . (2006). Distribution of breakpoints on chromosome 18 in breast, colorectal, and pancreatic carcinoma cell lines. Cancer Genet Cytogenet 164: 97–109.

    Article  CAS  Google Scholar 

  • Bast Jr RC, Hennessy B, Mills GB . (2009). The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9: 415–428.

    Article  CAS  Google Scholar 

  • Bayani J, Brenton JD, Macgregor PF, Beheshti B, Albert M, Nallainathan D et al. (2002). Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. Cancer Res 62: 3466–3476.

    CAS  PubMed  Google Scholar 

  • Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK . (2000). The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275: 23899–23903.

    Article  CAS  Google Scholar 

  • Curto M, McClatchey AI . (2008). Nf2/Merlin: a coordinator of receptor signalling and intercellular contact. Br J Cancer 98: 256–262.

    Article  CAS  Google Scholar 

  • Etemadmoghadam D, deFazio A, Beroukhim R, Mermel C, George J, Getz G et al. (2009). Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res 15: 1417–1427.

    Article  CAS  Google Scholar 

  • Hanahan D, Weinberg RA . (2000). The hallmarks of cancer. Cell 100: 57–70.

    Article  CAS  Google Scholar 

  • Herzog TJ . (2004). Recurrent ovarian cancer: how important is it to treat to disease progression? Clin Cancer Res 10: 7439–7449.

    Article  CAS  Google Scholar 

  • Herzog TJ, Pothuri B . (2006). Ovarian cancer: a focus on management of recurrent disease. Nat Clin Pract Oncol 3: 604–611.

    Article  CAS  Google Scholar 

  • Hofmann WK, Komor M, Wassmann B, Jones LC, Gschaidmeier H, Hoelzer D et al. (2003). Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood 102: 659–661.

    Article  CAS  Google Scholar 

  • Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV et al. (1994). A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436–440.

    Article  CAS  Google Scholar 

  • Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C et al. (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537–549.

    Article  CAS  Google Scholar 

  • Khalique L, Ayhan A, Weale ME, Jacobs IJ, Ramus SJ, Gayther SA . (2007). Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol 211: 286–295.

    Article  CAS  Google Scholar 

  • Kobel M, Huntsman D, Gilks CB . (2008). Critical molecular abnormalities in high-grade serous carcinoma of the ovary. Expert Rev Mol Med 10: e22.

    Article  Google Scholar 

  • Langdon SP, Lawrie SS, Hay FG, Hawkes MM, McDonald A, Hayward IP et al. (1988). Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res 48: 6166–6172.

    CAS  PubMed  Google Scholar 

  • Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G et al. (2009). Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 15: 559–565.

    Article  CAS  Google Scholar 

  • Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S et al. (1991). Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9: 389–393.

    Article  CAS  Google Scholar 

  • McAlpine JN, Eisenkop SM, Spirtos NM . (2008). Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays. Gynecol Oncol 110: 360–364.

    Article  CAS  Google Scholar 

  • Merlo LM, Pepper JW, Reid BJ, Maley CC . (2006). Cancer as an evolutionary and ecological process. Nat Rev Cancer 6: 924–935.

    Article  CAS  Google Scholar 

  • Mullighan CG, Phillips LA, Su X, Ma J, Miller CB, Shurtleff SA et al. (2008). Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322: 1377–1380.

    Article  CAS  Google Scholar 

  • Nowell PC . (1976). The clonal evolution of tumor cell populations. Science 194: 23–28.

    Article  CAS  Google Scholar 

  • Ouellet V, Zietarska M, Portelance L, Lafontaine J, Madore J, Puiffe ML et al. (2008). Characterization of three new serous epithelial ovarian cancer cell lines. BMC Cancer 8: 152.

    Article  Google Scholar 

  • Paige AJ, Taylor KJ, Taylor C, Hillier SG, Farrington S, Scott D et al. (2001). WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci USA 98: 11417–11422.

    Article  CAS  Google Scholar 

  • Roschke AV, Stover K, Tonon G, Schaffer AA, Kirsch IR . (2002). Stable karyotypes in epithelial cancer cell lines despite high rates of ongoing structural and numerical chromosomal instability. Neoplasia 4: 19–31.

    Article  Google Scholar 

  • Ruijter ET, van de Kaa CA, Schalken JA, Debruyne FM, Ruiter DJ . (1996). Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol 180: 295–299.

    Article  CAS  Google Scholar 

  • Sakai W, Swisher EM, Jacquemont C, Chandramohan KV, Couch FJ, Langdon SP et al. (2009). Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res 69: 6381–6386.

    Article  CAS  Google Scholar 

  • Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C et al. (2008). Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451: 1116–1120.

    Article  CAS  Google Scholar 

  • Schulmann K, Mori Y, Croog V, Yin J, Olaru A, Sterian A et al. (2005). Molecular phenotype of inflammatory bowel disease-associated neoplasms with microsatellite instability. Gastroenterology 129: 74–85.

    Article  CAS  Google Scholar 

  • Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A et al. (2009). Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461: 809–813.

    Article  CAS  Google Scholar 

  • Shibata K, Mori M, Tanaka S, Kitano S, Akiyoshi T . (1998). Identification and cloning of human G-protein gamma 7, down-regulated in pancreatic cancer. Biochem Biophys Res Commun 246: 205–209.

    Article  CAS  Google Scholar 

  • Swanton C, Marani M, Pardo O, Warne PH, Kelly G, Sahai E et al. (2007). Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 11: 498–512.

    Article  CAS  Google Scholar 

  • Swanton C, Nicke B, Schuett M, Eklund AC, Ng C, Li Q et al. (2009). Chromosomal instability determines taxane response. Proc Natl Acad Sci USA 106: 8671–8676.

    Article  CAS  Google Scholar 

  • Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T . (2008). Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 68: 2581–2586.

    Article  CAS  Google Scholar 

  • Torres L, Ribeiro FR, Pandis N, Andersen JA, Heim S, Teixeira MR . (2007). Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases. Breast Cancer Res Treat 102: 143–155.

    Article  Google Scholar 

  • Toyoda M, Shirato H, Nakajima K, Kojima M, Takahashi M, Kubota M et al. (2003). Jumonji downregulates cardiac cell proliferation by repressing cyclin D1 expression. Dev Cell 5: 85–97.

    Article  CAS  Google Scholar 

  • Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM et al. (1993). A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 75: 826.

    Article  CAS  Google Scholar 

  • Turner N, Tutt A, Ashworth A . (2004). Hallmarks of ′BRCAness′ in sporadic cancers. Nat Rev Cancer 4: 814–819.

    Article  CAS  Google Scholar 

  • Zhu YM, Foroni L, McQuaker IG, Papaioannou M, Haynes A, Russell HH . (1999). Mechanisms of relapse in acute leukaemia: involvement of p53 mutated subclones in disease progression in acute lymphoblastic leukaemia. Br J Cancer 79: 1151–1157.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Paul Edwards for helpful discussion of the paper. We thank our patients and members of the Gynaecological Oncology Multidisciplinary Team at Cambridge University Hospitals NHS Foundation Trust for their participation in the CTCR-OV01 clinical study. This work was funded by Cancer Research UK. We acknowledge the support of the University of Cambridge, Hutchison Whampoa Ltd, the Cambridge Experimental Cancer Medicine Centre and the NIHR Biomedical Research Centre.

Author information

Authors and Affiliations

  1. Cancer Research UK Cambridge Research Institute, Li Ka Shing Center, Cambridge, UK

    S L Cooke, C K Y Ng, M J Garcia, T Hardcastle, J Temple & J D Brenton

  2. British Columbia Cancer Agency, Centre for Translational and Applied Genomics, Vancouver, British Columbia, Canada

    N Melnyk & D Huntsman

  3. Division of Pathology, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK

    S Langdon

Authors
  1. S L Cooke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C K Y Ng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N Melnyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M J Garcia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Hardcastle
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Temple
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Langdon
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D Huntsman
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J D Brenton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J D Brenton.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cooke, S., Ng, C., Melnyk, N. et al. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene 29, 4905–4913 (2010). https://doi.org/10.1038/onc.2010.245

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2010.245

Keywords

This article is cited by

Search

Advanced search

Quick links